Spyre Therapeutics, Inc. SYRE Cash, Cash Equivalents, and Marketable Securities
Cash, Cash Equivalents, and Marketable Securities at other companies
Other financials
Where this comes from
Reported directly by Spyre Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition.
The official record: Spyre Therapeutics, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Spyre Therapeutics, Inc.'s cash, cash equivalents, and marketable securities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Spyre Therapeutics, Inc.'s cash, cash equivalents, and marketable securities?
- Spyre Therapeutics, Inc. (SYRE) reported cash, cash equivalents, and marketable securities of $432M in Q1 2026.
- How has Spyre Therapeutics, Inc.'s cash, cash equivalents, and marketable securities changed year-over-year?
- Spyre Therapeutics, Inc.'s cash, cash equivalents, and marketable securities increased by 310.8% year-over-year, from $105.15M to $432M.
- What is the long-term trend for Spyre Therapeutics, Inc.'s cash, cash equivalents, and marketable securities?
- Over 3 years (2022 to 2025), Spyre Therapeutics, Inc.'s cash, cash equivalents, and marketable securities has grown at a 93.0% compound annual growth rate (CAGR), from $25.17M to $180.96M.
- What does cash, cash equivalents, and marketable securities mean?
- This represents the most liquid assets held by the company, including cash on hand, bank deposits, and short-term investments that can be readily converted into cash. It serves as the primary buffer for operational liquidity and potential capital allocation activities. Investors monitor this to assess the company's ability to meet short-term obligations and fund growth initiatives.